RhAPPcast: CD64+ Binding Description, Relevance, and Potential Clinical Implications

Welcome to RhAPPcast, the official podcast for Rheumatology Advanced Practice Providers (RhAPP). In this episode, Amanda Mixon, PA-C, RhAPP President, sits down with William Saalfeld, NP, to discuss the evolving science of IL-23 inhibition and CD64 binding in psoriatic arthritis (PsA), psoriasis, and inflammatory bowel disease (IBD).CD64 upregulation plays a significant role in immune cell activation and inflammation in rheumatic diseases. IL-23 is a key driver of chronic inflammation in the joints, skin, and gut, fueling disease progression in PsA, psoriasis, and IBD. The latest advancements in targeted therapy reveal how IL-23 inhibitors, such as Guselkumab (Tremfya®), utilize CD64 binding to enhance efficacy and improve clinical outcomes.This discussion explores how CD64 dual binding may refine treatment precision, offering better control of inflammation in PsA, psoriasis, and IBD. Understanding these immunologic pathways is critical for optimizing therapy selection, especially for complex patients requiring tailored treatment approaches.Stay connected and informed—subscribe to RhAPPcast on your favorite podcast platform and visit RhAPP.org for educational content, expert faculty insights, and practice resources. Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.